FHA
ALLO icon

Flagship Harbor Advisors’s Allogene Therapeutics ALLO Stock Holding History

Flagship Harbor Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-203
Closed -$7K – 606
2020
Q3 		$7K Hold
203
– – ﹤0.01% 1419
2020
Q2 		$8K Hold
203
– – ﹤0.01% 1406
2020
Q1 		$4K Sell
203
-40
-16% -$953 ﹤0.01% 1442
2019
Q4 		$6K Hold
243
– – ﹤0.01% 1461
2019
Q3 		$6K Buy
243
+68
+39% +$1.94K ﹤0.01% 1417
2019
Q2 		$4K Hold
175
– – ﹤0.01% 1532
2019
Q1 		$5K Buy
+175
New +$5.08K ﹤0.01% 1474

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Flagship Harbor Advisors's ALLO Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Allogene Therapeutics (ALLO) in Q4 2020, closing a stake of 203 shares — an estimated $7K sold.

Flagship Harbor Advisors first reported a position in ALLO in Q1 2019 and held it in 7 quarters. The position peaked at $8K in Q2 2020. 165 funds tracked by Wall St. Rank hold ALLO as of Q4 2020.

  • Flagship Harbor Advisors reported no remaining Allogene Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 203 Allogene Therapeutics shares in Q4 2020, an estimated $7K.
  • Flagship Harbor Advisors first reported a position in Allogene Therapeutics in Q1 2019 and held it in 7 quarters.
  • Flagship Harbor Advisors's Allogene Therapeutics position peaked at $8K in Q2 2020.
  • 165 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.